The European Medicines Agency has started reviewing the EU marketing authorization applications for a new batch of products, including Regeneron’s Otarmeni, which has been granted an accelerated assessment.
The European Medicines Agency has started reviewing the EU marketing authorization applications for a new batch of products, including Regeneron’s Otarmeni, which has been granted an accelerated assessment.